Eli Lilly has announced plans to acquire Kelonia in a deal valued at $7 billion. This acquisition reflects Lilly's strategic interests in expanding its portfolio.
The agreement includes an upfront payment of $3.25 billion, which is expected to be paid before any potential investment opportunities for outside investors arise.
This move may present a chance for investors to engage early in what could be a significant transaction in the pharmaceutical sector.